Epigenetic de novo methylation of CpG islands is an important event in malignant transformation. Two genes are frequently methylated: cyclin-dependent kinase inhibitor 2B (CDKN2B) and cyclin-dependent kinase inhibitor 2A (CDKN2A). In our study methylation of these genes was studied in 63 patients with myelodysplastic syndromes (MDS), 2 with myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and 13 with acute myeloid leukemia (AML). Five patients were monitored during 5-azacytidine treatment. Twenty-six healthy donors were tested in a control group. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) method with all associated techniques was used for detection. Aberrant methylation was present in the CDKN2A gene in 38% and in the CDKN2B gene in 77% of the patients in MDS group. The level of methylation was higher in the group of AML patients -77% in CDKN2A gene and 100% in CDKN2B gene. In MDS patients, an aberrant methylation was associated with a tendency to disease progression towards more advanced forms according to the World Health Organization (WHO) classification and the International Prognostic Scoring System (IPSS). Significant differences in methylation level were observed between early and advanced forms of MDS in CDKN2B gene (P value < 0.05) but not for CDKN2A gene. The trend of methylation in patients treated with azacitidine was analyzed in CDKN2B gene and correlated with the course of the disease. Increased methylation was connected with disease progression. We concluded that the methylation level of CDKN2B gene might be used as a marker of leukemic transformation in MDS. Our study indicates the role of hypermethylation as an important event in the progression of MDS to AML.
Epigenetic changes are important events in leukemia patogenesis (1) . DNA methylation is one of the most common alterations in leukemia. The potential role of DNA methylation as a biomarker in leukemia has not yet been proven (2) . In the human genome, methylated cytosines are found in CpG dinucleotides whose palindromic nature allows for the maintenance of methylation patterns by DNA methyltransferases following semi-conservative replication of DNA. CG-rich regions also known as CpG islands are located mostly in the promoter regions of genes and are generally unmethylated in healthy tissues (3, 4) . Their methylation is associated with transcriptional silencing of genes (5, 6, 7) . Methylation changes belong to the most studied epigenetic events in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The most frequently tested genes are CDKN2B gene (cyclin-dependent kinase inhibitor gene, p15 INK4B ) and its functional homologue CDKN2A gene. CDKN2A gene generates several transcript variants which differ in their first exons (isoform 1 called p16 INK4A and isoform 4 called p14 ARF ) (7, 8) . Their function is to regulate cell cycle by inhibition of cyclindependent kinases 4 and 6, which control the progression of cells from G1 to S phase. Hypermethylation of 5´-CpG islands within the promoter regions was described as an alternative mechanism of CDKN2A/CDKN2B gene inactivation (7, 9 ). An increased hypermethylation of the CDKN2A and CDKN2B promotor regions was found during disease progression and was associated with leukemic transformation and poor prognosis (8) .
Myelodysplastic syndromes are a group of clonal hematopoietic disorders. Their pathogenesis is attributed to the important role of an initial damage to hematopoietic stem cells, which ultimately leads to the formation of pathological clone and a growth advantage. This disorder is characterized by pancytopenia due to ineffective hematopoiesis and dyspla-sia of hematopoietic cells (10, 11) . The increased incidence of mutations of oncogenes stimulates proliferation and differentiation of early precursor depressants of hematopoiesis as a consequence of genome instability, leading to a gradual increase in the number of blasts at an advanced stage of disease and the transition into acute myeloid leukemia. Diagnostic criteria have been set up in two classification systems: (the French-American-British [FAB] and the World Health Organization [WHO] ) and in several prognostic-scoring systems, the most widely used being the International Prognostic Scoring System (IPSS) (12) . The latest revision of the WHO classification of myeloid neoplasms and acute leukemias was published in 2008 (13, 14) .
Treatment with hypomethylating agents and inhibitors of histone deacetylases is an alternative approach to therapy of MDS patients with intermediate-2 or high-risk MDS patients who are not indicated for combination chemotherapy and allogeneic stem cell transplantation (SCT) (15, 16) . 5-Azacytidine and decitabine are currently available hypomethylating agents (15, 17, 18) . Hypomethylating agents are phosphorylated and incorporated into DNA (as 5-aza-dCTP) during S phase, where they covalently bind to the DNA methyltransferases (DNMTs). They are irreversibly inhibiting their function, leading to the progressive loss of methylation; this process requires that the cell go through S phase (12) . Treatment with hypomethylating agents has been shown effective in almost 50% of treated patients (15) .
Patients and methods
Patients. The methylation status of the CDKN2B and CDKN2A genes was studied in DNA samples isolated from bone marrow mononuclear cells (BM)-MNCs from 78 Czech patients (39 men and 39 women, median age 59 years; range, 20 -79 years) with MDS and AML, including 44 cases of refractory cytopenia with multilineage dysplasia (RCMD), 4 cases of refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS), 7 cases of refractory anemia with excess blasts-1 (RAEB-1), 8 cases of refractory anemia with excess blasts-2 (RAEB-2), 2 cases of myelodysplastic/ myeloproliferative neoplasms (MDS/MPN) and 13 cases of acute myeloid leukamia (AML). Methylation status was also analyzed in 47 DNA samples extracted from peripherial blood (PB) from 5 patients with demethylation treatment: 1 patient with MDS/MPN and 4 patients with AML treated with 5-azacytidine (Vidaza®, Celgene Corp., Summit, USA) in the dose of 75mg/m 2 /d for 7 days every 28 days. Patients with demethylation treatment were monitored continuously during treatment. Twenty-six DNA samples from healthy donors (HD) were used as non-malignant controls. The diagnosis and classification of the MDS were performed according to the WHO 2008 (13) . The study was approved by the ethical committee of the Institute of Hematology and Blood Transfusion. All patients and control subjects signed an informed consent to participate in this study. (20) . The kit contains 43 different probes -20 probes for the CDKN2A-CDKN2B genes -of which 9 are methylation specific (Table 1) , 3 probes for the MTAP gene, 7 probes between MTAP and the 9p telomere region, 2 digestion control probes and 11 reference probes for data analysis. In addition, 9 control fragments are included (http://www.mrc-holland. com) [cit. 11-04-24]). MLPA probes for methylation quantification are similar to normal MLPA probes, except that the sequence detected by the MS-MLPA probe contains the sequence recognized by the methylation-sensitive restriction enzyme HhaI. Extracted genomic DNA (20-200 ng) was used, according to the instructions of the manufacturer (MRC-Holland, Amsterdam, Netherlands). Methylated hybrids of sample DNA were prevented from being digested by HhaI, and then amplified by PCR. Products were analyzed by capillary electrophoresis on an ABI 3500 automatic sequencer (Applied Biosystems, Foster City, CA, USA). If the DNA samples are methylated, proportional peak is visible; on the other hand, if the DNA samples are unmethylated, probes do not generate a signal.
Isolation
Data and statistical analysis. A MS-MLPA probe targets a single specific HhaI site in a CpG island; if methylation is absent for a particular CpG-site, this does not necessarily mean that the whole CpG island is unmethylated. Therefore, two approaches are possible while analyzing the results: either to evaluate every single probe or to evaluate the whole gene and average out all probes within this particular gene. We used both methods for data analysis. Data normalization and analysis were performed using the Coffalyser software developed at MRC-Holland (Jordy Coffa, MSc., MRC-Holland, Bio Informatics Research Scientist). Statistical data processing was performed using Table 2 and Figure 1 and in Table 3 are levels of methylation of each patient´s populations and healthy donors. The results showed 38% aberrant methylation in the CDKN2A gene and 78% in the CDKN2B gene in patients with MDS and 77% in CDKN2A gene and 100% in CDKN2B gene in the group of patients with AML. 
Yes
Statistical comparisons between different subtypes of MDS, AML and IPSS groups were made for each single probe and also for the gene in 9p21 region. P values for the genes are shown in Table 4 .
Methylation analysis of the CDKN2B gene in five patients treated with 5-azacytidine (Vidaza). We analyzed methylation status in 47 samples from five patients during the hypomethylation treatment -four patients with AML and one patient with MDS/MPN. The trend of methylation status was monitored in CDKN2B gene, especially in the 130 bp probe (probe 11867-L12664, the coding region of exon 1). On the basis of a previous analysis of 78 patients this probe was capable of corresponding with disease progression.
The trend of methylation changes in individual patients and the correlation with the disease progression or remission of the disease is described in detail in legend of Figure 2 . The methylation changes were only subtle, in the range of 1 -5 percent. The correlation of disease progression was particularly shown in patients P1 and P3, where the level of methylation had increased by 11% after 11th cycle of the treatment in patient P1 and by 6% after 9th cycle of treatment in patient P3.
Discussion
Silencing of proliferation-associated genes by aberrant hypermethylation is often found in neoplasia. In the present study we have shown that hypermethylation is an important event in the progression of MDS to AML. Two issues were addressed. Firstly, the intensity of methylation of CDKN2A-CDKN2B genes in different subtypes of MDS according to WHO classification and IPSS score has been studied. Secondly, the response of patients to the treatment with hypomethylation agents was evaluated.
We analyzed the intensity of methylation of CDKN2A and CDKN2B genes according to diagnosis and IPSS score. All the results were compared with the results obtained from healthy controls. The sample was considered as unmethylated, if all the probes for the gene were without methylation. Aberrant methylation was detected in 38% in CDKN2A gene and in 78% in CDKN2B gene in patients with MDS according to (21) . Furthermore, there are also reports from other authors who showed that the value of methylation of CDKN2B gene was in the range of 40 -60% in MDS patients (7, 8, 11, 22) . Aggerholm et al. (2006) found methylation of CDKN2B gene in 51% of MDS patients (22) . Our results are slightly different, the percentage of methylation being higher. This is probably due to the fact that the MS-MLPA method that we have used, and the very kit ME-024, contains 43 probes selectively for CDKN2A and 2B gene regions. Solomon et al. ) gene of MDS patients. They used a method of semi-nested multiplex PCR and primers located in the CpG rich islands of the promoter at least 500 bp upstream of the transcription start site, enclosing at least one HpaII restriction site (8) . The examined group of patients was smaller than our one; however, the results obtained in this study were very similar to our results. Uchida et al. (1997) showed that no apparent hypermethylation of CDKN2A (p16 INK4A ) gene was detected in patients with MDS (11) while in our study we detected methylation in 38% of MDS patients. This could be caused by the different design of primers used in these two studies. Our methylation probes were designed to detect methylation in regions located nearer the gene of interest while Uchida used primers located in a different region of interest.
The level of methylation was increasing in accordance with IPSS score (from low-risk to intermediate-2-risk patients), except for the high-risk group. In this group the level of methylation was 14.8% in CDKN2B gene, however, in the intermediate-2-risk group the level was 20.6%. This result is most likely due to the small number of patients (only four) in the high-risk group and this could be the source of bias. Other studies detected an increase of methylation intensity continu- ally from low-risk to high-risk (7, 11) and we suppose that we would observe the same trend if more patients had been included. These results support our current understanding of the mechanism of methylation and its role in neoplasia, as it was proposed by Herman et al. (1996, 1997) On the other hand, the level of expression of protooncogenes, angiogenic, anti-apoptic genes and genes of signal transduction was increased. They have concluded, that overexpression of these genes might be important for a malignant clone expansion in MDS patients (24) . Twenty-two of our patients were included in their study. The link between our study and the study of Vasikova et al. (2010) is that level of methylation and expression of several transcription factors is closely related. The level of methylation, which was detected in our study, showed increasing trend in our patients (at RCMD 4.8%, at RAEB-1 17.2% and RAEB-2 26.3%). Concurrently, there was detected firm adherence in trend of downregulation of transcription factors E2F1 and E2F2 from the early to advanced forms of MDS (at RCMD -1.1x, at RAEB-1 -1.7x and RAEB-2 -2.4x than healthy controls).
Our study focused on monitoring the intensity of methylation in patients treated with the hypomethylation agent 5-azacytidine. Based on the results of our previous analysis of seventy-eight samples, we decided to monitor the methylation status only in the CDKN2B gene, especially in 130 bp probe. This probe is located in exon 1a, whose HhaI site is located 33 base pairs before the first methionine. Other probes coding for CDKN2B gene are the 220 bp probe, whose HhaI site is located 100 base pairs before the first methionine, or the 417 bp probe located 155 bp before the exon 1a. The most consistent results were obtained for the 130 bp probe and we speculate that this probe might be located in an important area, the closest to the coding region of the CDKN2B gene. We suppose that this region might play an important role in the regulation of the CDKN2B gene. However, further experiments are needed.
In the group of patients treated with 5-azacytidine, the trend of methylation partly correlated with disease progression, but the methylation changes were only subtle. In our study, two from five patients achieved partial remission while the three remaining patients progressed. The results of other studies are fairly consistent, showing about 40% of patients responding to treatment with hypomethylating agents (25, 26) .
Allogeneic SCT is the only treatment modality in MDS, but is available only for selected patients depending mainly on the amount of the bone marrow blasts, comorbidities, suitable donor and other criteria (15, 18) . For patients who are not indicated for combination therapy and allogeneic SCT or do not have a suitable donor for SCT, 5-azacytidine represents a new treatment option. Results from the literature show that treatment with 5-azacytidine may be effective in patients with intermediate-2 and high-risk MDS because of prolongation of overall survival (15, 18, 27) . 5-Azacytidine has been observed to produce better responses in patients with unfavourable cytogenetics and was effective in reducing the risk of disease relapse or in the treatment AML relapse after allogeneic SCT (15, 18, 28, 29) . There are also reports supporting the feasibility and effectiveness of 5-azacytidine treatment in patients with lower-risk MDS (16). 5-Azacytidine has been also used as a first line treatment in patients with de novo acute myeloid leukemia similarly as several patients in our cohort.
In summary, aberrant methylation in the CpG islands was present frequently in the CDKN2B gene and increase of methylation was accompanied by disease progression. Thus, the methylation level of this gene might be used as a marker of leukemic transformation in MDS (1). Our study indicates an important role of hypermethylation in the progression of MDS to AML.
